Enzymatic Synthesis of Peptide Nanofibers for Self-Delivery of Indomethacin and Tyroservatide in Cancer Therapy

Divalent metal ion modulation of a simple peptide-based hydrogel: self-assembly and viscoelastic properties

Peptide self-assembly has been highly studied to understand the pathways in forming higher order structures along with the development and application of resulting hydrogel materials. Driven by noncovalent interactions, peptide hydrogels are stimuli-responsive to any addition to its gelling conditions. Here, a Phe-His based peptide, C14-FH(Trt)-OH, was synthesized and characterized with 1H NMR, FT-IR, MS, UV-vis spectroscopies and elemental analysis. Based on SEM imaging, the dipeptide conjugate was capable of forming a nanofibrous, interconnected network encapsulating buffer to produce a supramolecular hydrogel. Through the addition of Zn2+ and Cu2+, there is a clear change in the self-assembled nanostructures characterized through SEM. With this effect on self-assembly follows a change in the viscoelastic properties of the material, as determined through rheological frequency sweeps, with 2 and 3 orders of magnitude decreases in the elastic modulus G' in the presence of Zn2+ and Cu2+ respectively. This highlights the tunability of soft material properties with peptide design and self-assembly, through metal ions and Nδ-directed coordination.

Peptide Assemblies for Cancer Therapy

Supramolecular assemblies made by the self-assembly of peptides are finding an increasing number of applications in various fields. While the early exploration of peptide assemblies centered on tissue engineering or regenerative medicine, the recent development has shown that peptide assemblies can act as supramolecular medicine for cancer therapy. This review covers the progress of applying peptide assemblies for cancer therapy, with the emphasis on the works appeared over the last five years. We start with the introduction of a few seminal works on peptide assemblies, then discuss the combination of peptide assemblies with anticancer drugs. Next, we highlight the use of enzyme-controlled transformation or shapeshifting of peptide assemblies for inhibiting cancer cells and tumors. After that, we provide the outlook for this exciting field that promises new kind of therapeutics for cancer therapy.